https://scholars.lib.ntu.edu.tw/handle/123456789/630859
標題: | Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab | 作者: | CHIUN HSU Ducreux, Michel Zhu, Andrew X Qin, Shukui Ikeda, Masafumi Kim, Tae-You Galle, Peter R Finn, Richard S Chen, Ethan Ma, Ning Hu, Youyou Li, Lindong ANN-LII CHENG |
關鍵字: | Atezolizumab; Bevacizumab; Post hoc analysis; Viral flare; Viral reactivation | 公開日期: | 二月-2023 | 出版社: | KARGER | 卷: | 12 | 期: | 1 | 起(迄)頁: | 44 | 來源出版物: | Liver cancer | 摘要: | In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. We used IMbrave150 data to investigate the safety and risk of viral reactivation or flare in infected patients treated with atezolizumab + bevacizumab or sorafenib. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630859 | ISSN: | 2235-1795 | DOI: | 10.1159/000525499 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。